Dr. Simon Frey
TitleCited byYear
Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations
D Achelrod, U Wenzel, S Frey
American journal of hypertension 28 (3), 355-361, 2015
The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching
S Frey
European Psychiatry 29 (8), 479-489, 2014
Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature
S Frey, CR Blankart, T Stargardt
PharmacoEconomics 34 (5), 479-498, 2016
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
S Frey, Linder, Juckel
European Journal of Health Economics, 2013
Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds
S Frey, T Stargardt
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32 (10 …, 2012
Durch Blutungen verursachte Kosten bei der Therapie des akuten Koronarsyndroms in Deutschland
A Bufe, S Frey, S Briswalter
Herz Kardiovaskuläre Erkrankungen 34 (6), 479-484, 2009
The Economic burden of cystic fibrosis in Germany from a payer perspective
S Frey, T Stargardt, U Schneider, J Schreyögg
PharmacoEconomics 37 (8), 1029-1039, 2019
Costs caused by bleeds within the therapy of acute coronary syndromes in Germany
A Bufe, S Frey, S Briswalter
Herz 34 (6), 479-484, 2009
Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework
D Müller, A Gerber-Grote, B Stollenwerk, S Stock, PWP Auweiler, S Frey, ...
Expert review of pharmacoeconomics & outcomes research 16 (5), 619-627, 2016
PMH16 Analysis of the Economic Burden and Cost Structure of Schizophrenia in Germany Using Observational Sickness Fund Data
S Frey, R Linder, T Stargardt
Value in Health 15 (7), A336, 2012
Peer-reviewed publications
S Frey
Has Pharmaceutical Innovation Increased Persistence and Adherence of Multiple Sclerosis Patients in Germany?
KE Fischer, S Frey, F Lichtenberg
Value in Health 19 (7), A437, 2016
Economic Evaluation of Health Technologies Using Administrative Data
S Frey
AD1 Compliance Measurement Using Administrative Data From German Sickness Funds
S Frey, T Stargardt
Value in Health 14 (7), A233, 2011
PMH36 Cost-Effectiveness of Depot Flupentixol Versus Long-Acting Risperidone–A Markov Model Parameterized Using Administrative Data
S Frey, T Stargardt, R Linder, G Juckel
Value in Health 14 (7), A293, 2011
26. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA)
G Walter, A Wienke, S Gregor
24th Annual Meeting of the German Drug Utilisation Research Group (GAA)
S Frey, F Lichtenberg
The system can't perform the operation now. Try again later.
Articles 1–17